Compare BHST & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | NSPR |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3M | 39.4M |
| IPO Year | 2017 | 2009 |
| Metric | BHST | NSPR |
|---|---|---|
| Price | $1.89 | $0.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $4.00 |
| AVG Volume (30 Days) | 43.7K | ★ 89.9K |
| Earning Date | 05-15-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,310,000.00 |
| Revenue This Year | $146.27 | $57.98 |
| Revenue Next Year | N/A | $95.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $0.63 |
| 52 Week High | $12.80 | $2.57 |
| Indicator | BHST | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 35.52 | 47.73 |
| Support Level | $1.82 | $0.66 |
| Resistance Level | $2.99 | $1.03 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 12.16 | 7.79 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.